Article Text

Download PDFPDF
Overview
  1. E Chew
  1. Lead clinician, Building 31, Room 6A52, 31 Center Drive, MSC 2510, Bethesda, MD 20892-2510, USA; echew@nei.nih.gov

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This patient has both medical and ocular conditions that need to be addressed. It is important to emphasise the need to improve his glycaemic control. This information should be communicated to his primary care physician to initiate tighter control of his glycaemia. In the UK Prospective Diabetes Study (UKPDS), the largest and longest randomised study of intensive v conventional glucose control in patients with type 2 diabetes, there was a 25% reduction in the risk of the “any diabetes related microvascular end point,” including the need for retinal photocoagulation in the intensive treatment group compared with the conventional treatment group.1 After 6 years of follow up, a smaller proportion of patients in the intensive treatment group than in the conventional group had a two step progression (worsening) in diabetic retinopathy (p<0.01). Epidemiological analysis of the UKPDS data showed a continuous relation between the risk of microvascular complications and glycaemia, such that for every percentage point decrease in HbA1c (for example, 9% to 8%), there was a 35% reduction in the risk of microvascular complications.

    Although the data from the Diabetes Control and Complications Trial (DCCT) are from patients with type 1 diabetes, the results showed the importance as well as the persistent effects of glucose control in preventing the progression of the severity of diabetic retinopathy and the development of macular oedema.2 Following the completion of the controlled …

    View Full Text